Gastroesophageal reflux disease (GERD) is a prevalent gastrointestinal condition affecting a significant portion of the global population. While GERD rarely leads to death, untreated cases can result in serious complications, including esophageal ulcers, bleeding, strictures, and Barrett’s esophagus, which increases the risk of esophageal cancer. Severe cases may require surgical intervention, costing between $8000 and $12,000. For patients with milder symptoms, proton pump inhibitors (PPIs) are often prescribed as a cost-effective treatment, averaging $163 per month, or $1500 to $2000 annually. However, PPIs are often misused, and their effectiveness is limited, reducing only about 65% of stomach acid. Misuse can lead to adverse effects, such as low stomach acid, indigestion, gas, diarrhea, constipation, and long-term risks like kidney disease, dementia, bone fractures, and cardiovascular disorders. Therefore, a more controlled approach to treatment is needed, utilizing drug delivery devices that minimize human error and comply with FDA and other regulatory standards to ensure patient safety. This paper explores recent advancements in GERD diagnosis and management, highlighting the potential of a patented device titled “A Swallowable Medical Device” that could revolutionize GERD treatment. This paper compares traditional diagnostic methods, such as endoscopy, pH monitoring, and esophageal manometry, with modern approaches like impedance-pH monitoring and high-resolution manometry. These advanced technologies allow healthcare providers to tailor treatment strategies to individual patient needs, enabling more accurate and comprehensive assessments. Additionally, a comparison with other patented devices is provided to facilitate understanding. The aim of this analysis is to offer insights into current practices, innovations, and the efficacy of the proposed “Swallowable Medical Device”. This information is made available globally to encourage further research and development in the field of GERD treatment.